IBD Outcomes
Our focus on performing epidemiological and outcomes research in inflammatory bowel diseases (IBD) is motivated by a desire to better understand the factors that drive favorable or unfavorable clinical outcomes in IBD.
Several avenues of active investigation include the following domains:
- The effect of fatty liver disease on IBD
- Assessment of the impact of different diagnostic and therapeutic algorithms in IBD
- Identification and testing of novel therapies
Related publications
- Fansiwala K, Spartz EJ, Roney AR, Kwaan MR, Sauk JS, Chen PH, Limketkai BN. Increasing rates of bowel resection surgery for stricturing Crohn's disease in the biologic era. Inflammatory Bowel Diseases. 25 May 2024
- Spartz EJ, DeDecker LC, Fansiwala KM, Noorian S, Roney AR, Hakimian S, Sauk JS, Chen PH, Limketkai BN. Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023 Oct 24
- Prakash P, Dua A, Blumenfeld Y, Chen PH, Parian AM, Limketkai BN. Longitudinal trends in pregnancy outcomes among women with inflammatory bowel disease in the ear of biologics: A 20-year nationwide analysis. Inflamm Bowel Dis 2023 Oct 19
- Tripathi K, Godoy-Brewer G, Thu Nguyen M, Singh Y, Saleh Ismail M, Sauk JS, Parian AM, Limketkai BN. COVID-19 and outcomes in patients with inflammatory bowel disease: Systematic review and meta-analysis. Inflamm Bowel Dis 2022;28(8):1265-79
- Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg 2021;25(1):211-9
- Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases: nationwide analysis. Inflamm Bowel Dis 2021